BAM15 vs 5-amino-1mq

BAM15 (C-tier) vs 5-amino-1mq (C-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

BAM15 · tier C

a preclinical mitochondrial protonophore that reduced fat gain and improved metabolic measures in mice, with no human exposure, dose-finding, or safety study.

BAM15 has a coherent mechanism and credible mouse metabolic data, but no human bridge and no basis for calling a research-chemical exposure safe.

0 human exposure studies · half-life 1.7 hours in mouse plasma after 10 mg/kg oral gavage; no human half-life · weight loss

5-amino-1mq · tier C

5-amino-1MQ is a small molecule NNMT inhibitor, not a peptide. People seek it for fat loss, but every administration and outcome study located for this review was in animals.

Subcutaneous mouse studies found lower weight or fat gain. There is no human administration evidence, so human benefit, adverse effects, and a safe exposure are unknown.

NNMT inhibitor, preclinical · half-life no human pharmacokinetic measurement; rat and mouse values differ by route and are kept separate · weight loss

at a glance

• BAM15: tier C · 0 human exposure studies
• 5-amino-1mq: tier C · NNMT inhibitor, preclinical

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.